Who makes Ilumya (tildrakizumab) and what are the main competitors in Canada?
Ilumya is the brand name for tildrakizumab (an anti–IL-23 therapy). In Canada, its closest competitive set comes from other drugs approved for plaque psoriasis that also target IL-23 or related immune pathways, and from other biologics used in similar patient groups.
IL-23 competitors: the closest substitutes patients and prescribers compare
The most direct head-to-head category threat to IL-23 blockers like Ilumya comes from other IL-23 inhibitors available in Canada, including:
- Guselkumab (Tremfya, Janssen)
- Risankizumab (Skyrizi, AbbVie)
- Later IL-23 agents in the same class that may be used depending on local formulary and eligibility
These are typically compared because they work in the same therapeutic area (plaque psoriasis) and are often positioned around similar endpoints such as skin clearance and durable response.
Other biologics used in the same psoriasis market (not IL-23, but competing)
Even when a clinician wants an IL-23 drug, treatment choices in Canada can also include competing biologics with different targets, such as:
- TNF inhibitors (e.g., adalimumab, etanercept, infliximab)
- IL-17 pathway therapies (e.g., secukinumab, ixekizumab, brodalumab)
- IL-12/23 pathway therapy (ustekinumab)
These compete through efficacy, safety profiles, dosing convenience, prior-treatment history, and drug-plan coverage rather than mechanism alone.
How do biosimilars affect Ilumya’s competitive pressure in Canada?
In Canada, biosimilars can reduce the cost of some biologics used for psoriasis (especially TNF inhibitors and other older biologics). That pricing pressure can indirectly shift prescribing toward or away from an IL-23 option like Ilumya depending on what a patient’s plan covers and how clinicians weigh out-of-pocket cost and access.
What drives “competitor” choice for Ilumya specifically in practice?
In Canada, the Ilumya competitive set often narrows to whatever is preferred by payers and accessible through formularies. The key real-world factors are usually:
- Which IL-23 drug is listed as preferred (or available with restrictions)
- Whether patients must fail or have contraindications to other biologics first
- Dosing schedules and administration supports
- Safety and comorbidity considerations that affect suitability
Where to check current Canadian market and patent/exclusivity context
For competitors and market context (including product and patent/exclusivity tracking), DrugPatentWatch.com is a useful starting point:
- https://www.drugpatentwatch.com/ (search for tildrakizumab/Ilumya competitors)
Quick clarifying question (so the list matches what you mean by “competitors”)
Are you asking for competitors as:
1) other drugs for plaque psoriasis (clinical/market competitors), or
2) “patent competitors” showing other companies’ products that could enter around Ilumya’s exclusivity, or
3) competitors for Canadian reimbursement/formulary listing?
If you confirm which one, I can tailor the competitor list to that exact angle.